Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a Study of OVX033 Sarbecovirus Vaccine in Adults
2024-517396-20-00Phase 2Authorised
- Sponsor
- Osivax
- Start
- Jan 2025
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OVX033 in Sarbecovirus infection and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Osivax. Primary endpoints: Solicited local and systemic symptoms per subject (Phase 1), Solicited local and systemic symptoms per dose (Phase 1) and 8 more. Planned start Jan 2025; status: authorised.
02
Drugs
OVX033
03
Conditions
Sarbecovirus infectioncoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-517396-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517396-20-00.